Biopharmaceutical business AstraZeneca, US, has entered into a three-year collaboration agreement with US-based pharmaceutical and healthcare information provider IMS Health. The deal seeks to advance the use of real-world evidence based on observational and retrospective studies throughout Europe to inform the delivery of effective and cost-efficient healthcare.
The partnership with IMS Health is expected to give AstraZeneca access to pre-existing anonymised electronic health records, which include clinical outcome, economic and treatment pattern data. In addition, the companies will jointly develop a customised research and data analysis platform. The information will provide a deeper insight into how medicines that are already on the market are working in real-world settings across Europe, painting a picture of unmet needs in the current standard of care and treatment patterns across a number of therapeutic areas, with an emphasis on chronic illnesses. The data will also be used to inform AstraZeneca's discovery and clinical development programmes.
The announcement builds on AstraZeneca's existing 'real-world' data and research partnership with HealthCore in the US, the health outcomes research subsidiary of WellPoint. The financial terms of the collaboration agreement were not disclosed.
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
